Press Releases Jaguar Health, Inc.

Equities

JAGX

US47010C8881

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:07:34 10/02/2026 am IST			5-day change	1st Jan Change
0.6640 ^USD	-0.90%		+4.89%	-27.90%

16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI

Press Releases

15/01	Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts	AQ
12/01	Jaguar Health : Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million	PU
11/12	FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs	AQ
11/12	Jaguar Health : Corporate Presentation – December 10, 2025 (4f076c)	PU
10/12	Jaguar Health : FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs	PU
09/12	Jaguar Health : Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders	PU
21/11	Jaguar Health : Corporate Presentation – November 17, 2025 (ca884a)	PU
17/11	Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue	PU
15/11	Jaguar Health : Proxy Statement (dfe8db)	PU
26/25/26	Jaguar Health : Corporate Presentation – September 26, 2025 (ba7a24)	PU
22/25/22	Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs	AQ
18/25/18	Jaguar Health : Supplement to Proxy Statement (a14554)	PU
14/25/14	Jaguar Health : Corporate Presentation - August 14, 2025 (fc7ef2)	PU
21/25/21	Jaguar Health : Proxy Card (eeedf7)	PU
21/25/21	Jaguar Health : Proxy Statement (a70aac)	PU
12/25/12	First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs	AQ
28/25/28	Jaguar Health : Corporate Presentation – May 23, 2025 (03bb7b)	PU
22/25/22	Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	AQ
14/25/14	Jaguar Health : Corporate Presentation – May 13, 2025 (0fdab9)	PU
09/25/09	Jaguar Health : Corporate Presentation – May 8, 2025 (8aebcc)	PU
26/25/26	Jaguar Health : Corporate Presentation – April 25, 2025 (3b0648)	PU
09/25/09	Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product	AQ
02/25/02	Jaguar Health : Announces Closing of Bridge Financing Priced At The Market Under Nasdaq Rules	PU
31/25/31	Jaguar Health : Corporate Presentation – April 1, 2025	PU
27/25/27	Jaguar Health : Meeting with FDA Regarding Results of Phase 3 OnTarget Study	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Jaguar Health, Inc.

Equities

JAGX

US47010C8881

Pharmaceuticals

Press Releases

Filters